Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer
Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer
复制标题
DOI：
10.1007/s13277-015-4567-8
复制
发表时间：
2016-06
期刊：
影响因子：
--
通讯作者：
J. Zhong;Yan Chen;Xinhui Liao;Jiaqiang Li;Han Wang;Chenglong Wu;Xiaowen Zou;Gang Yang;Jing-feng Shi;Liya Luo;Litao Liu;Jianping Deng;A. Tang
中科院分区：
文献类型：
--
作者：
J. Zhong;Yan Chen;Xinhui Liao;Jiaqiang Li;Han Wang;Chenglong Wu;Xiaowen Zou;Gang Yang;Jing-feng Shi;Liya Luo;Litao Liu;Jianping Deng;A. Tang
由于治疗选择有限且复发率高，膀胱癌呈现出高死亡率。因此，免疫疗法等新型治疗方法已成为延长患者总体生存期并实现疾病治愈的有希望的治疗方式，这重新燃起了人们对肿瘤特异性靶抗原鉴定的热情。癌症睾丸（CT）抗原因其表达特征和高免疫原性而被认为是免疫治疗的理想靶标。在这里，我们研究了一种新型 CT 抗原——睾丸表达 19 (TEX19) 在膀胱癌患者和多个人体组织中的表达模式。还分析了六种膀胱癌细胞系（T24、UM-UC-3、J82、5637、SW780 和 RT4）的 TEX19 表达。我们的结果表明，正常组织中的 TEX19 表达仅限于人类睾丸。此外，在 60% (24/40) 的膀胱癌样本中检测到 TEX19mRNA 表达，而 58.20% (110/189) 的 TEXT19 蛋白表达呈阳性。与低级别肿瘤相比，TEX19 在高级别肿瘤中的表达增加，分别从 53.69% 增加到 77.14%（P= 0.011）。 TEX19 也在所有六种膀胱癌细胞系中表达。总之，我们的研究结果表明，TEX19 代表一种新的 CT 基因，可能在膀胱癌的进展中发挥作用，因此该基因为膀胱癌的免疫治疗策略提供了潜在的靶点。
Bladder cancer exhibits high mortality as a result of limited therapeutic options and a high recurrence rate. Accordingly, novel treatments such as immunotherapy have emerged as promising therapeutic modalities to prolong overall patient survival and effect a disease cure, which has renewed enthusiasm for the identification of tumor-specific target antigens. Cancer-testis (CT) antigens are recognized as ideal targets for immunotherapy because of their expression features and high immunogenicity profiles. Here, we investigate the expression pattern of a novel CT antigen, testis-expressed 19 (TEX19), in patients with bladder carcinoma and among multiple human tissues. Six bladder cancer cell lines (T24, UM-UC-3, J82, 5637, SW780, and RT4) were also analyzed for TEX19 expression. Our results reveal that TEX19 expression in normal tissue is restricted to human testis. In addition,TEX19mRNA expression was detected in 60 % (24/40) bladder cancer samples, whereas 58.20 % (110/189) were positive for TEXT19 protein expression. Compared to low-grade tumors, TEX19 exhibited increased expression in high-grade tumors, from 53.69 to 77.14 %, respectively (P= 0.011). TEX19 was also expressed in all six bladder cancer cell lines. Together, our findings suggest thatTEX19represents a novel CT gene and might play a role in the progression of bladder cancer and that this gene therefore provides a potential target for immunotherapy treatment strategies against bladder cancer.